The Company

Omniose was founded in 2016 based on the pioneering glycoconjugation discoveries of our scientific founders Mario Feldman and Christian Harding through a scientific collaboration that characterized a new class of conjugating enzymes.  The research operations were established at BioGenerator Labs in St. Louis and the company was previously known as VaxNewMo.  Omniose has been awarded $11.8 million in grants from the US NIAID for use of our platform technology to develop vaccines against Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae.

In January 2024, the company announced an exclusive collaboration agreement with AstraZeneca for up to three years to research potential vaccines for bacterial pathogens.

Meet our Leadership Team

Timothy Cooke, Ph.D., M.B.A.
Chief Executive Officer
Christian Harding, Ph.D.
Chief Scientific Officer
& Co-Founder
Roman Fleck, Ph.D., M.B.A.
Mario Feldman, Ph.D.
Co-Founder &
Scientific Advisory Board Member
Christine Szymanski, Ph.D.
Steven Projan, Ph.D.
Scientific Advisory Board Member